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The aim of this work is to evaluate simple, sensitive, effective and validated procedures for the 
determination of cefotaxime, cefoperazone, ceftazidime and cefadroxil. In this study, the methods based 
on the ability of the cited drugs to reduce Ag+ ions to silver nanoparticles (Ag-NPs) in the presence of 
Polyvinyl Pyrrolidone (PVP) as a stabilizing agent producing very intense surface plasmon resonance 
peak of Ag-NPs (λmax. = 410-430 nm). The plasmon absorbance of the Ag-NPs allows the quantitative 
spectrophotometric determination of the cited drugs. The calibration curves are linear with concentration 
ranges of 0.4-3.2, 1-8, 0.5-4.0 and 1.5-9.0 µg/mL for cefotaxime, cefoperazone, ceftazidime and cefadroxil, 
respectively. Apparent molar absorptivity, detection and quantitative limits are calculated. Applications 
of the proposed methods to representative pharmaceutical formulations are successfully presented. The 
extracellular synthesis of nanoparticles is fast, and the method doesn’t require various elaborate treatments 
and tedious extraction procedures.
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INTRODUCTION
Cefo t ax ime  sod ium [ sod ium (6R , 7R ) -3 -
[(acetyloxy)methyl]-7-[[(2Z)-2-(2-aminothiazole-4-
yl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate] (Indian 
Pharmacopoeia Government of India,2006 )(Figure 1), is 
an antibiotic used to treat a number of bacterial infections. 
Especially, it is used to treat joint infections, pelvic 
inflammatory diseases, meningitis, pneumonia, urinary 
tract infections, sepsis, gonorrhea, and cellulitis. It is given 
either by injection into a vein or a muscle (The American 
Society of Health-System Pharmacists, 2016).
Literature survey reveals several spectroscopic 
(Patel, Patel, Patel, 2006; Rao, Kumar, 2001), HPLC 
(Barker, 2003; Jolanta, Buszman, Hawranek, 2002; 
Victoria, Emmanouil, 2008), TLC (Nabi, Laiq, 2004) and 
HPTLC (Nanda et al., 2010), methods for the estimation of 
cefotaxime sodium individually as well as in combination 
with other drugs.
Cefoperazone sodium is a third-generation 
semisynthetic antibiotic that is used in the treatment 
of mild to moderate infections caused by susceptible 
microorganisms (Reynolds, 1998). It is official in USP 
(United States Pharmacopoeia, 1985), Chemically, 
ce foperazone  sodium is  7 - [R{2-(4-e thy l -2 ,3-
dioxopiperazin-1-yl carboxamide)-2-(4-hydroxylphenyl)
acetamide}-3-[1-methyl-1H-tetrazol-5-yl-thiomethyl]]-
3-cephem-4-carboxilate (British Pharmacopoeia, 2005) 
(Figure 1). Various analytical methods are applied for the 
determination of cefoperazone. These methods include 
spectrophotometry (Hoang et al., 2014; Sha et al., 2013) 
and HPLC (Lalitha, Puranik, Pai, 2009).
Ceftazidime is a semisynthetic cephalosporin of 
the third generation with a high antibacterial activity that 
widely used in the treatment of commonly-occurring 
bacterial infections, including indole-positive Proteus 
species and Pseudomonas aeruginosa that have been 
considered to be the drugs of choice for serious infections 
caused by Klebsiella, Enterobacter, Proteus, Providencia, 
Serratia and Haemophylus species (Claridge et al., 2007), 
Chemically, (Rodenas et al.,). Chemically, it is designated 
as (6R,7R)-7-[[2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-
carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-
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(pyridine-1-ium-ylmethyl)-5-thia-1-azabicyclo[4.2.0]
oct-ene-2-carboxylate. Several analytical procedures are 
available in the literature for the analysis of cephalosporins 
(ceftazidime). These methods are spectrophotometry 
(Amin, Ragab, 2004),  high performance l iquid 
chromatography (Zivanovic et al.,), and capillary 
electrophoresis (Castaneda, Julien, Fabra, 1996).
Cefadroxil is a semi-synthetic antibiotic belonging 
to the class of first-generation cephalosporins. Its 
mechanism of action is due to inhibition of the synthesis of 
the cell wall of mainly gram-positive bacteria being widely 
used for the treatment of infections such as pharyngitis, 
tonsillitis, gonorrhea, skin, soft tissue, ear and urinary 
tract (Devaliya, Jain, 2009). Chemically, it is designated 
as 5-thia-1-azabicyclo [4.2.0] oct-2-enecarboxylic acid, 
7- [[amino[4-hydroxyphenyl) acetyl] amino]-3-methyl-8-
oxo-, monohydrate, [6R[6-alpha,7-beta(R*)]]) (Figure 1), 
(Viswanath, Hemanth, 2017). Different methods are 
reported for the determination of cefadroxil including 
HPLC (Anjum et al., 2012), and spectrophotometry 
(El-Gindy, El Walily, Bedair, 2002; Shukla et al., 2008) 
(Figure 1).
Nanoparticles are one of the novel drug delivery 
systems, which can be of potential use in controlling and 
targeting drug delivery as well as in cosmetics textiles 
and paints. Nanoparticles have many advantages; they 
can be administered by parenteral, oral, nasal, ocular 
routes, by attaching specific ligands on their surfaces, 
nanoparticles can be used for directing the drugs to specific 
target cells, improving the stability and therapeutics index 
and reducing toxic effects. Nanoparticles have many 
applications, e.g. cancer therapy, intra cellular targeting, 
vaccine adjuvant, DNA delivery and ocular delivery. 
Nanoparticles made of silver and gold have been 
the focus of research for many decades as a result of their 
intriguing optical properties. When the nanoparticles 
disperse in liquid media, they exhibit a strong UV-vis 
extinction band that is not present in the spectrum of 
the bulk metal. Recently, the colorimetric nanoparticles 
have been developed for sensitive and selective detection 
of nebivolol (Rahman et al., 2013), fexofenadine 
(Rahnama, 2013), catecholamines (Tashkhourian, Nezhad, 
Khodaveisi, 2011), etilefrine hydrochloride, fenoterol 
hydrobromide, salbutamol sulphate and estradiol valerate 
(Magda et al.,2015), and fluroroquinolones (Sayed et 
al.,2017).
In this work, nanoparticles are used in quantitative 
determination of drugs; a simple, sensitive, effective 
and validated procedures for the determination of   was 
developed.
MATERIAL AND METHODS
Instrumentation
Shimadzu – UV 1800 double beam UV–Visible 
spectrophotometer (Japan) with matched 1 cm quartz 
cells at 200–800 nm range is used for all absorbance 
measurements. Spectra are automatically obtained by 
Shimadzu UV-Probe 2.32 system software.
FIGURE 1 - Chemical Structure of the studied drugs
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Jenway 6305 UV/Visible Spectrophotometer 
(England).
Material and Reagents
The used chemicals are of the highest purity; 
Cefotaxime (obtained from Tabuk Pharmaceutical 
Company, Tabuk, Saudi Arabia), Cefoperazone (obtained 
from Sigma-tec Pharmaceutical Industries, Egypt), 
Ceftazidime (obtained from Pharco B International 
Company, Alexandria, Egypt), Cefadroxil (obtained 
from Pharco B International Company, Alexandria, 
Egypt) and Silver nitrate, 0.02M aqueous solution, 
polyvinylpyrrolidone (PVP), 0.14% aqueous solution, 
sodium hydroxide, 0.0025M aqueous solution.
Pharmaceutical preparations
Curisafe® tablets containing 1 g cefadroxil 
momnohydrate per tablet with a batch No. 25612 (obtained 
from Pharco B International Company, Alexandria, 
Egypt). 
Duricef® Capsules containing 250 mg cefadroxil 
monohydrate per capsule with a batch No. 19077 (obtained 
from Glaxosmithkline, Egypt).
Cefoperazone® vials containing 0.538 cefoperazone 
sodium equivalent to cefoperazone anhydrous 0.5 
gm with a batch No. 26597 (obtained from Sigma-tec 
Pharmaceutical Industries, Egypt). 
Cefzim® vials containing 1 g ceftazidime 
pentahydrate with a batch No. 21956 (obtained from 
Pharco B International Company, Alexandria, Egypt).
Foxime® vials containing 1 g cefotaxime sodium 
equivalent to 1 g cefotaxime with a batch No. 23065 
(obtained from Tabuk Pharmaceutical Company, Tabuk, 
Saudi Arabia).
Standard solutions 
Solutions of 100 µg/mL of cefotaxime, cefoperazone, 
ceftazidime and cefadroxil are prepared by dissolving 10 
mg of the pure drug in bi-distilled water. 
General procedure
In 5 mL volumetric flask, appropriate amounts of 
silver nitrate, PVP, different concentrations of the cited 
drugs and appropriate amounts of NaOH are added, 
completed to 5 mL with bi-distilled water, and then 
heated in the water bath at 90 oC for appropriate times. 
Absorbance is measured at the suitable wavelength against 
reagent blank treated similarly (Table I).
Assay of pharmaceutical preparations 
Assay of tablets
For Curisafe® tablets: Ten tablets are weighed, 
coat removed and pulverized into fine powder, specific 
quantity of powdered drugs equivalent to 10 mg pure 
drug is dissolved in distilled water, solutions are filtered 
and diluted to 100 mL with distilled water then further 
dilution to 10 µg/mL and procedures are completed as in 
general procedures.
Assay of vials 
For Cefoperazone®, Cefzim® and Foxime® 
vials, the content of four vials for each drug is weighed 
and pulverized into fine powder, specific quantity 
of powdered drugs equivalent to 10 mg pure drug is 
dissolved in distilled water, solutions are filtered and 
diluted to 100 mL with distilled water then further 
dilution to 10 µg/mL and procedures are completed as 
in general procedures.
TABLE I – The analytical parameters for the determination of cefotaxime, cefoperazone, ceftazidime and cefadroxil through 
silver nanoparticles formation
Parameter Cefotaxime Cefoperazone Ceftazidime Cefadroxil
ʎmax.(nm) 410 430 430 410
Volume of Silver nitrate (0.02 M), mL 0.5 0.7 0.7 1.0
Volume of PVP (0.14%), mL 1.0 0.7 0.7 0.5
Volume of NaOH (0.0025 M), mL 0.7 1.0 1.0 0.7
Temperature, oC 90 90 90 90
Time of reaction, min. 30 30 35 25
Beer’s law limits (µg/mL) 0.4-3.2 1.0-8.0 0.5-4.0 1.5-9.0
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Assay of capsules 
For Duricef® Capsules, evacuating the content of 
ten capsules and pulverizing into fine powder, specific 
quantity of powdered drugs equivalent to 10 mg pure 
drug is dissolved in distilled water, solutions are filtered 
and diluted to 100 mL with distilled water then further 
dilution to 10 µg/mL and procedures are completed as in 
general procedures.
RESULTS AND DISCUSSIONS
Nanoparticles made of silver have been the focus of 
research for many decades due to their intriguing optical 
properties. The systems in this study consist of an aqueous 
AgNO3 solution that includes polyvinylpyrrolidone 
(PVP), as a stabilizer, at an alkaline medium. Cefotaxime, 
cefoperazone, ceftazidime and cefadroxil act as effective 
reducing agents for the reduction of silver metal salt (Ag+) 
to the Ag-NPs without adding any seeds.
In the absorbance of reducing agents, there is no 
absorbing peak in visible region (380-700 nm). Upon the 
addition of the cited drugs which act as a reducing agent, 
silver ions reduced to silver nanoparticles and then the 
absorbance characteristic of the plasmon of the Ag-NPs 
is observed (410-430 nm) (Figure 2). 
Effect of NaOH concentration
The influence of pH on Ag+ reduction by the cited 
drugs is expected since they have a hydroxyphenyl group 
which can lose H+ during oxidation and O-quinone 
formation process. Because the buffered condition failed to 
obtain silver nanoparticles, we added NaOH for providing 
enough alkalinity. By addition of NaOH, absorbance 
increases up to a known concentration of NaOH then 
decreases the formation of black precipitate which might 
be due to the Ag2O formation. Thus, 0.7 mL of 0.0025 M 
NaOH was selected the optimum NaOH concentration for 
cefotaxime and cefadroxil, while 1mL of 0.0025 M NaOH 
is sufficient for cefoperazone and ceftazidime.
Effect of Silver nitrate concentration 
Maximum absorbance values are obtained using 0.5, 
0.7, 0.7 and 1.0 mL of 0.02 M, silver nitrate for cefotaxime, 
cefoperazone, ceftazidime and cefadroxil, respectively.
Effect of Stabilizer type and concentration
An important issue in the preparation of metal 
nanoparticles is the choice of the capping agent used to 
protect or stabilize the nanoparticle colloidal metals from 
agglomeration. Size and morphology of nanoparticles 
are depending significantly on capping materials. 
Nanoparticles stabilization is achieved according to the 
two basic modes: electrostatic and steric stabilization 
(Bradley, Bradely, Weinheim, 1994). Electrostatic 
stabilization is caused by the columbic repulsion among 
particles, caused by the electrical double layer formed by 
ions adsorbed at the particle surface (e. g., sodium citrate) 
and the corresponding counter ions. Steric stabilization 
is achieved because of the coordination of sterically 
demanding organic molecules and polymers that acts as 
protective shields on the metallic surface (e. g., PVP). 
In this study, PVP and sodium citrate were selected 
as stabilizers for preventing of silver nanoparticles 
agglomeration in which the PVP is used in a better way 
comparing to the sodium citrate. 1.0, 0.7, 0.7 and 0.5 mL of 
0.14 % PVP were optimum for cefotaxime, cefoperazone, 
ceftazidime and cefadroxil, respectively.
Effect of temperature and time of heating
Heating in water bath at 90 oC for 30, 30, 35 and 25 
min are sufficient to produce maximum color intensities 
for cefotaxime, cefoperazone, ceftazidime and cefadroxil, 
respectively.
FIGURE 2 - Absorbance spectra of the silver nanoparticles 
formed in the presence of: 4.5 µg/mL cefadroxil (––––), 
5 µg/mL cefoperazone (––––), 1.6 µg/mL cefotaxime (––––) 
and 2.5 µg/mL ceftazidime (––––). 
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Method of validation
Linearity
Under the described experimental conditions, 
standard calibration curves with good linearity for silver 
nanoparticles formed using cefotaxime, cefoperazone, 
ceftazidime and cefadroxil are constructed by plotting 
absorbance against concentration.
A linear correlation is found. The concentration 
ranges, correlation coefficient, intercept and slope 
for the calibration curve are calculated. Also, relative 
standard deviation, detection and quantification limits are 
calculated and listed in tables (Tables II, III).
The validity of the proposed method was assessed 
by its application to the determination of the cited drugs 
in their pharmaceutical preparations, (Tables IV, V, VI).
Student’s t-test and F-test (at 95% confidence level) 
are applied to the results obtained and compared with 
that obtained from reported methods (Hesham et al., 
2006; Hesham, 2004). The results show that there are no 
significant differences between the proposed and reported 
methods. The results of different statistical treatment of the 
data are shown in (Table VII).
Accuracy and precision
Accuracy and precision are carried out by six 
determinations at two different concentrations of the four 
drugs in the same day (intra-day), and in six different days 
(inter-day). 
The results of accuracy and precision (Table VIII) 
show that the proposed methods have good repeatability 
and reproducibility.
TABLE II – The spectral data for the determination of cefotaxime, cefoperazone, ceftazidime and cefadroxil through silver 
nanoparticles formation 
Parameter Cefotaxime Cefoperazone Ceftazidime Cefadroxil
Linearity range (µg/mL) 0.4-3.2 1.0-8.0 0.5-4.0.0 1.5-9.0
Limit of detection LOD (µg/mL) 0.12 0.33 0.13 0.33
Limit of quantitation LOQ (µg/mL) 0.35 0.89 0.39 1.00
Slope (b) 0.4069 0.1134 0.2231 0.0536
Intercept (a) -0.0009 -0.0014 -0.0017 0.0007
Correlation coefficient (r) 0.9999 0.9997 0.9998 0.9999
Calculated on the basis of the molecular weight of the drug A= a+bc
TABLE III – The determination of cefotaxime, cefoperazone, ceftazidime and cefadroxil through silver nanoparticles formation
Statistics
Cefotaxime Cefoperazone Ceftazidime Cefadroxil
Taken
(µg/mL)
Recovery
%
Taken
(µg/mL)
Recovery
%
Taken
(µg/mL)
Recovery
%
Taken
(µg/mL)
Recovery
%
0.4 98.36 1.0 100.88 0.5 101.04 1.5 98.63
0.8 100.42 2.0 100.70 1.0 101.08 3.0 101.55
1.2 100.08 3.0 100.63 1.5 100.19 4.5 100.04
1.6 100.44 4.0 100.18 2.0 99.52 6.0 99.06
2.0 99.52 5.0 98.13 2.5 100.57 7.5 99.57
2.4 100.10 6.0 100.59 3.0 99.76 9.0 100.39
2.8 99.52 7.0 99.70 3.5 99.83
3.2 100.37 8.0 100.57 4.0 100.55
Mean* 99.85 100.17 100.32 99.87
N 8 8 8 6
V 0.54 0.63 0.49 0.79
±S.D. 0.73 0.79 0.70 0.89
R.S.D. 0.74 0.79 0.70 0.89
*Mean of three different experiments
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TABLE IV - The determination of cefotaxime, cefoperazone, ceftazidime and cefadroxil in their pharmaceutical formulations
Statistics
Foxime® vials Cefoperazone®vials Cefzim®vials Duricef®Capsules Curisafe® tablets
Cefotaxime Cefoperazone Ceftazidime Cefadroxil Cefadroxil
T
(µg/mL)
R*
%
T
(µg/mL)
R*
%
T
(µg/mL)
R*
%
T
(µg/mL)
R*
%
T
(µg/mL)
R*
%
0.4 97.81 1.0 98.11 0.5 98.11 1.5 97.55 1.5 99.91
0.8 99.12 2.0 99.51 1.0 99.14 3.0 99.01 3.0 98.09
1.2 99.53 3.0 101.51 1.5 100.51 4.5 99.14 4.5 100.79
1.6 100.14 4.0 100.51 2.0 99.11 6.0 99.91 6.0 101.09
2.0 98.95 5.0 99.79 2.5 99.71 7.5 99.51 7.5 100.94
2.4 99.56 6.0 99.51 3.0 101.01 9.0 100.61 9.0 98.75
2.8 99.77 7.0 98.91 3.5 99.81
3.2 100.78 8.0 99.99 4.0 100.57
Mean* 99.46 99.73 99.75 99.29 99.93
N 8 8 8 6 6
V 0.62 0.72 0.73 0.72 1.01
±S.D. 0.79 0.85 0.86 0.85 1.00
R.S.D. 0.79 0.85 0.86 0.85 1.00
*Mean of three different experiments
TABLE V - Application of standard addition technique for the determination of cefotaxime, cefoperazone, ceftazidime in their 
pharmaceutical formulations
Duricef® Capsules Curisafe® Tablets
Taken
µg/mL
Added
µg/mL
Recovery*
%
Taken
µg/mL
Added
µg/mL
Recovery* 
% 
4.5 - 99.51 4.5 - 98.75 
4.5 100.73 4.5 99.09
6.0 99.51 6.0 100.74
7.5 101.51 7.5 101.11
Mean* 100.32 99.92
N 4 4
V 0.81 1.00
±S.D. 0.90 1.00
R.S.D. 0.89 0.99
*Mean of three different experiments
TABLE VI - Application of standard addition technique for the determination of cefadroxil in its pharmaceutical formulations
Foxime® vials Cefoperazone® vials Cefzim® vials 
Taken
µg/mL
Added
µg/mL
Recovery*
%
Taken
µg/mL
Added
µg/mL
Recovery*
%
Taken
µg/mL
Added
µg/mL
Recovery*
%
0.8 - 98.51 2.0 - 101.45 1.0 - 97.91
0.8 99.71 2.0 99.81 1.0 98.51
1.2 100.53 3.0 99.09 1.5 101.53 
1.6 99.87 4.0 99.91 2.0 101.34  
Mean* 99.66 100.07 100.07
N 4 4 4
V 0.57 0.65 0.69
±S.D. 0.75 0.81 0.83
R.S.D. 0.76 0.81 0.83
*Mean of three different experiments
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TABLE VII – The statistical data for the determination of cefotaxime, cefoperazone, ceftazidime and cefadroxil through silver 
nanoparticles formation
Statistics
Cefotaxime Cefoperazone Ceftazidime Cefadroxil
Suggested
Method
Reported
Method
Suggested
Method
Reported
Method
Suggested
Method
Reported
Method
Suggested
Method
Reported
Method
Mean* 99.85 99.50 100.17 99.22 100.32 99.19 99.87 99.53
N 8 5 8 5 8 5 6 5 
V 0.54 0.88 0.63 1.37 0.70 0.56 0.79 0.56
±S.D. 0.73 0.94 0.79 1.17 0.83 0.75 0.89 0.75
t 0.33 (2.201)* 0.45 (2.201) * 0.09 (2.201) * 0.35 (2.262) *  
F 1.63 (4.070) * 2.17 (4.070) * 1.25 (4.070) * 1.41 (4.760) *  
*Theoretical values of t and F at p =0.05
TABLE VIII - The intra-day and inter-day accuracy and precision data for the determination of cefotaxime, cefoperazone, ceftazidime 
and cefadroxil through silver nanoparticles formation 
Intra-day Inter-day
Taken
(µg/mL)
Found
(µg/mL)
Recovery
%
RSD
%
Taken
(µg/mL)
Found
(µg/mL)
Recovery
%
RSD
%
Cefotaxime 1.6 1.58 99.00 0.87 1.6 1.61 100.71 0.96
Cefoperazone 4.0 3.95 98.75 1.12 4.0 3.90 97.53 0.98
Ceftazidime 2.5 2.52 100.79 0.78 2.5 2.49 99.4 0.83
Cefadroxil 6.0 5.99 99.85 1.45 6.0 5.99 99.76 1.34
*Mean of six different experiments
CONCLUSION
Application of silver nanoparticles as chromogenic 
agent has been demonstrated in this work for the optical 
detection on the cited drugs based on the seedless 
production of Ag-NPs.
The proposed method is simple, sensitive and 
inexpensive for their determination. This analytical 
protocol may be an important green method for the 
monitor and the optical determination of cefotaxime, 
cefoperazone, ceftazidime and cefadroxil in pure and 
pharmaceutical dosage forms. 
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